Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia

Journal of Clinical Psychopharmacology

Volumn 31, Issue 2, 2011, Pages 256-258

  Walther, Sebastian ^a   Schüpbach, Brigitte ^a   Seifritz, Erich ^b   Homan, Philipp ^a   Strik, Werner ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DRONABINOL; LORAZEPAM; METOPROLOL; PIPAMPERONE; PLACEBO; SIMVASTATIN;

AGED; AGITATION; ALZHEIMER DISEASE; APATHY; CASE REPORT; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL FEATURE; COGNITIVE DEFECT; DELUSION; DEMENTIA; HUMAN; LETTER; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT RESPONSE; VERBAL HOSTILITY;

AGED; AGED, 80 AND OVER; AKATHISIA, DRUG-INDUCED; CROSS-OVER STUDIES; DEMENTIA; HUMANS; MALE; PSYCHOMOTOR AGITATION; TETRAHYDROCANNABINOL;

EID: 79952390569     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31820e861c     Document Type: Letter

References (17)

1. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475-1483.
2. Banerjee S, Murray J, Foley B, et al. Predictors of institutionalisation in people with dementia. J Neurol Neurosurg Psychiatry. 2003;74(9):1315-1316.
3. Volicer L, Harper DG, Manning BC, et al. Sundowning and circadian rhythms in Alzheimer's disease. Am J Psychiatry. 2001;158(5):704-711. (Pubitemid 32429836)
4. Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245-255.
5. Mahlberg R, Kunz D, Sutej I, et al. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol. 2004;24(4):456-459. (Pubitemid 38944151)
6. Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12(9):913-919. (Pubitemid 27420571)
7. Walther S, Mahlberg R, Eichmann U, et al. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl). 2006;185(4): 524-528.
8. Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int J Geriatr Psychiatry. 2008;23(1):116-117. (Pubitemid 351181617)
9. Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 2009;(2):CD007204. Review. PMID: 19370677.
10. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3): 189-198.
11. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944. (Pubitemid 14076461)
12. Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr. 1992;4(suppl 1):55-69.
13. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314. (Pubitemid 24382728)
14. Mahlberg R, Walther S, Eichmann U, et al. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study. Arch Gerontol Geriatr. 2007;45(1):19-26. (Pubitemid 46654257)
15. Van Someren EJ, Swaab DF, Colenda CC, et al. Bright light therapy: improved sensitivity to its effects on rest-activity rhythms in Alzheimer patients by application of nonparametric methods. Chronobiol Int. 1999;16(4): 505-518. (Pubitemid 29362572)
16. Murillo-Rodriguez E. The role of the CB1 receptor in the regulation of sleep. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1420-1427. (Pubitemid 352033665)
17. Walther S, Halpern M. Cannabinoids and dementia: a review of clinical and preclinical data. Pharmaceuticals. 2010;3:2689-2708. doi:10.3390/ph3082689.